FDA approves first biosimilar drug for cancer

FDA approves first biosimilar drug for cancer
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.

Mvasi (bevacizumab-awwb) was found to be biosimilar to the drug Avastin (bevacizumab), the FDA said Thursday in a news release. Avastin was approved in 2004. Mvasi is approved to treat certain colorectal, lung, brain, kidney, and cervical cancers.

The most common side effects of Mvasi include epistaxis, headache, hypertension, rhinitis, proteinuria, changes in taste, and dry skin. More serious could include perforation or fistula, arterial and venous thromboembolic events, and posterior reversible encephalopathy syndrome. Like Avastin, labeling for Mvasi will warn of increased risk of gastrointestinal perforations; complications after surgery; and severe or fatal pulmonary, gastrointestinal, central nervous system, and vaginal hemorrhage.

"Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower and increase access to important therapies," FDA Commissioner Scott Gottlieb, M.D., said in a statement. He pledged new biosimilar drugs would be brought to market quickly, although subject to the FDA's "rigorous gold standard for safety and effectiveness."

Mvasi's approval was given to Amgen, based in Thousand Oaks, Calif. Avastin is produced by Genentech.


Explore further

FDA clears Avastin for late-stage cervical cancer

More information: More Information

Health News Copyright © 2017 HealthDay. All rights reserved.

Citation: FDA approves first biosimilar drug for cancer (2017, September 15) retrieved 23 January 2019 from https://medicalxpress.com/news/2017-09-fda-biosimilar-drug-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more